ARDEA BIOSCIENCES, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1994-01-01
- Employees
- 107
- Market Cap
- -
- Website
- http://www.ardeabio.com
Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.
Phase 1
Completed
- Conditions
- Gout
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03272425
- Locations
- 🇧🇷
CAEP - Centro Avançado de Estudos e Pesquisas Ltda., Campinas, Sao Paulo, Brazil
Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02888054
RDEA3170 PK/PD Study
Phase 1
Completed
- Conditions
- Gout
- Interventions
- Drug: RDEA3170 4.5 mgDrug: RDEA3170 6 mgDrug: RDEA3170 12 mg
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02608710
Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: lesinurad/allopurinol 200/300 FDC tabletsDrug: lesinurad/allopurinol 200/200 FDC tablets
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT02581553
Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02498652
RDEA3170 Tablet and Capsule Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: RDEA3170,10 mgDrug: RDEA3170, 5 mgDrug: RDEA3170, 2.5 mgDrug: RDEA3170, 10 mg
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT02448368
IVIVR Assessing PK Parameters Used to Establish Bioequivalence
- First Posted Date
- 2015-03-25
- Last Posted Date
- 2016-01-01
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02398448
DECT Study in Allopurinol-Treated Gout Patients
Completed
- Conditions
- Gout
- Interventions
- Procedure: DECT scan
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 223
- Registration Number
- NCT02393560
RDEA3170 Bioavailability Study
Phase 1
Completed
- Conditions
- Gout
- Interventions
- Drug: RDEA3170 10 mgDrug: RDEA3170 2.5 mg
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02336594
RDEA3170 and Allopurinol Combination Study in Gout Subjects
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02279641